Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

NCT ID: NCT00855114

Last Updated: 2017-12-02

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-07-31
• Study Completion Date: 2009-06-30

Brief Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well everolimus works in treating women with breast cancer that can be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

• Determine whether the administration of everolimus results in a decrease of total choline, a surrogate marker of response, in at least 30% of women with resectable breast cancer.

Secondary

• Determine whether tumors with activated mTOR signaling, as measured by phosphorylation of 4E-BP1 and activity of cap dependent translational complex, will identify those women responsive to everolimus.

OUTLINE: Patients receive oral everolimus once daily on days 1-7 in the absence of disease progression or unacceptable toxicity. Within 24 hours after completing everolimus, patients undergo surgery.

Tumor tissue samples are collected at baseline and during surgery for the analysis of mTOR targets (i.e., 4E-BP1, p70S6 kinase phosphorylation), Ki67, cleaved caspase 3, and activity of cap dependent translational complex by immunohistochemical assays. Patients also undergo MRI/MRS before and after everolimus therapy for total choline and glucose levels measurement.

After completion of study therapy, patients are followed for 30 days.

Conditions

Breast Cancer

Keywords

stage II breast cancer; stage III breast cancer; stage IIIA breast cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients Treated with Everolimus

Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.

Group Type: EXPERIMENTAL

everolimus

Intervention Type: DRUG

5 mg/day x 7 days by mouth

therapeutic conventional surgery

Intervention Type: PROCEDURE

Definitive excision of breast cancer tissue

Interventions

everolimus

5 mg/day x 7 days by mouth

Intervention Type: DRUG

therapeutic conventional surgery

Definitive excision of breast cancer tissue

Intervention Type: PROCEDURE

Other Intervention Names

RAD001; Afinitor(R); surgery

Eligibility Criteria

Inclusion Criteria

• Diagnosis of invasive breast cancer

• Resectable disease
• Measurable disease, defined as a primary breast mass > 2.0 cm by breast imaging or clinical exam
• Planning to undergo surgical resection after neoadjuvant therapy
• Menopausal status not specified
• Eastern Clinical Oncology Group (ECOG) performance status 0-1
• Absolute neutrophil count (ANC) ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin > 9.0 g/dL
• Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 2.5 times upper limit of normal (ULN)
• Creatinine ≤ 1.5 times ULN
• Total bilirubin ≤ 1.5 times ULN
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception

Exclusion Criteria

• Intracranial disease
• Hormone receptor status not specified
• Obese (> 250 pounds)
• Immunosuppression from any cause (e.g., known HIV infection)
• History of severe asthma and/or allergies
• History of severe claustrophobia
• Ferromagnetic implants, history of shotgun wound and/or shrapnel, cardiac pacemakers, or other similar situations that would be contrary to strong magnetic force
• Bleeding diathesis
• Unstable systemic disease, including but not limited to, any of the following:

• Uncontrolled diabetes
• Severe infection
• Severe malnutrition
• Uncontrolled hypertension
• Unstable angina
• Ventricular arrhythmias
• Active ischemic heart disease
• Congestive heart failure
• Myocardial infarction within the past 6 months
• Chronic liver disease
• Renal disease
• Active upper gastrointestinal tract ulceration
• Less than 4 weeks since prior investigational drug
• Prior therapy with sirolimus or its analogues
• Concurrent immunosuppressive therapy (e.g., steroids, cytotoxic agents, or concurrent radiotherapy)
• Concurrent anticoagulation (i.e., coumadin)

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Masonic Cancer Center, University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Douglas Yee, MD

Role: PRINCIPAL_INVESTIGATOR

Masonic Cancer Center, University of Minnesota

Locations

University of Minnesota Children's Hospital - Fairview

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

0505M70026

Identifier Type: OTHER

Identifier Source: secondary_id

2005LS029

Identifier Type: -

Identifier Source: org_study_id